1832 Asset Management
ARRY

1832 Asset Management’s Array Biopharma Inc ARRY Stock Holding History

1832 Asset Management’s Portfolio ARRY Stock Details ARRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-1,602,300
Closed -$37.3M – 789
2019
Q1 		$37.3M Buy
+1,602,300
New +$33.4M 0.13% 147

Other funds holding ARRY

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

1832 Asset Management's ARRY Position: Q2 2019 in Review

1832 Asset Management sold out of Array Biopharma Inc (ARRY) in Q2 2019, closing a stake of 1,602,300 shares — an estimated $37.3M sold.

1832 Asset Management first reported a position in ARRY in Q1 2019 and held it in 1 quarter. The position peaked at $37.3M in Q1 2019. 319 funds tracked by Wall St. Rank hold ARRY as of Q2 2019.

  • 1832 Asset Management reported no remaining Array Biopharma Inc position as of Q2 2019 after selling out during the quarter.
  • 1832 Asset Management sold 1,602,300 Array Biopharma Inc shares in Q2 2019, an estimated $37.3M.
  • 1832 Asset Management first reported a position in Array Biopharma Inc in Q1 2019 and held it in 1 quarter.
  • 1832 Asset Management's Array Biopharma Inc position peaked at $37.3M in Q1 2019.
  • 319 funds tracked by Wall St. Rank held Array Biopharma Inc as of Q2 2019.

Based on 1832 Asset Management's 13F filing for Q2 2019, filed 14 Aug 2019.